Editorial Material
Medicine, General & Internal
Zhijun Zhou, Min Li
Summary: Targeted therapy is crucial for improving overall survival and reducing side effects in cancer treatment, but each patient responds differently to treatment. The development of cutting-edge technologies, such as next-generation sequencing, has allowed for the identification of more actionable targets. This special issue of BMC Medicine presents a collection of studies on targeted therapies for various cancer types, aiming to bridge the gap between genomic testing and precision medicine and spark innovations in improving the efficacy of targeted therapies.
Review
Oncology
Sahar F. Bannoura, Husain Yar Khan, Asfar S. Azmi
Summary: KRAS mutations are common in cancer, and recent advancements have shown that small molecule inhibitors can be developed against KRAS G12C, although there is still no agent to target KRAS G12D. However, significant progress has been made in developing compounds that can bind to and inhibit KRAS G12D, including MRTX1133. Additionally, an immunotherapeutic approach using adoptive T-cell transfer has shown promise in targeting G12D in pancreatic cancer.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Rayane Dennaoui, Hridaya Shrestha, Kay-Uwe Wagner
Summary: Pancreatic cancer research has made significant progress in understanding the molecular and developmental processes involved in the genesis of this highly malignant tumor type. Various models, including chemical carcingen-induced and genetically engineered animal models, are being developed and analyzed to study the biological significance of new molecular targets and mechanisms contributing to pancreatic cancer onset and progression.
CANCER AND METASTASIS REVIEWS
(2021)
Article
Multidisciplinary Sciences
Tetsuya Kadonosono, Kotaro Miyamoto, Shiori Sakai, Yoshiyuki Matsuo, Shojiro Kitajima, Qiannan Wang, Minori Endo, Mizuho Niibori, Takahiro Kuchimaru, Tomoyoshi Soga, Kiichi Hirota, Shinae Kizaka-Kondoh
Summary: By establishing cell models of quiescence, this study reveals the regulation of the transition between quiescent and proliferative states in tumor cells, which involves multiple signaling pathways and reduction of intracellular metabolites and energy demand in the quiescent state.
SCIENTIFIC REPORTS
(2022)
Review
Oncology
Anthony Turpin, Cindy Neuzillet, Elise Colle, Nelson Dusetti, Remy Nicolle, Jerome Cros, Louis de Mestier, Jean-Baptiste Bachet, Pascal Hammel
Summary: Mortality from pancreatic ductal adenocarcinoma is increasing worldwide and there is an urgent need for effective new treatments. The current treatment for fit patients with metastatic PDAC is based on two chemotherapy combinations that were validated more than 8 years ago. Although treatments targeting specific molecular alterations have largely failed in unselected patients, encouraging results have been observed in subpopulations with certain mutations or gene fusions. Targeted tumor metabolism therapies and immunotherapy have been disappointing but are still being investigated in combination with other drugs. Optimizing pharmacokinetics and adapting available chemotherapies based on molecular signatures are promising avenues of research. Continuous search for actionable vulnerabilities in PDAC tumor cells and microenvironments may lead to more personalized therapeutic approaches.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Cell Biology
Hellen Kuasne, Luisa Matos do Canto, Mads Malik Aagaard, Juan Jose Moyano Munoz, Camille De Jamblinne, Fabio Albuquerque Marchi, Cristovam Scapulatempo-Neto, Eliney Ferreira Faria, Ademar Lopes, Sebastien Carreno, Silvia Regina Rogatto
Summary: In this study, five human primary penile cancer-derived cell cultures were established, including two epithelial and three cancer-associated fibroblast (CAF) cells. Epithelial penile cancer-derived cells showed good response to cisplatin and CAF signature markers were identified in CAF cells, indicating their suitability for penile cancer microenvironment studies.
Article
Pharmacology & Pharmacy
O. Ngozi Nwaefulu, S. Rao Sagineedu, M. Kaisarul Islam, J. Stanslas
Summary: Pancreatic cancer is a difficult-to-treat disease with a high fatality rate. End-stage pancreatic cancer currently has no specific treatment, but surgery, radiation, and chemotherapy can extend patients' survival. This article summarizes various targeted therapies for pancreatic cancer, including the use of inhibitors and monoclonal antibodies.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2022)
Review
Endocrinology & Metabolism
Yu Gu, Tung Bui, William J. Muller
Summary: Breast cancer recurrence and metastasis remain major challenges for disease treatment. Understanding the biology of dormant tumors and cancer cells is crucial for overcoming clinical obstacles. Mouse models, particularly immunocompetent transgenic models, offer versatility and potential for studying the mechanisms of dormancy and developing therapeutic strategies.
Review
Oncology
Yuriko Saiki, Can Jiang, Masaki Ohmuraya, Toru Furukawa
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy and a major cause of cancer-related deaths worldwide. Recent multi-gene analysis methods have provided valuable insight into the molecular characteristics of pancreatic tumors, with different types of pancreatic cancer and precursor lesions showing specific molecular alterations. Genetically engineered mouse models (GEMMs) driven by oncogenic Kras have proven to be useful in understanding the roles of altered genes and recapitulating key features of human PDAC.
Review
Chemistry, Multidisciplinary
Hai-feng Hu, Zeng Ye, Yi Qin, Xiao-wu Xu, Xian-jun Yu, Qi-feng Zhuo, Shun-rong Ji
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with high mortality rate due to lack of early diagnosis measures and strong resistance to chemotherapy. Research focus is on studying the functions of key driver genes and their clinical implications for further application.
ACTA PHARMACOLOGICA SINICA
(2021)
Article
Medicine, Research & Experimental
Thomas Wilson, Giacomo Pirovano, Gu Xiao, Zachary Samuels, Sheryl Roberts, Tara Viray, Navjot Guru, Pat Zanzonico, Marc Gollub, Naga Vara Kishore Pillarsetty, Thomas Reiner, Jill Bargonetti
Summary: The PARP inhibitor 123I-MAPi shows promise for the systemic treatment of p53 mutant cancers, delivering therapeutic levels of Auger radiation without significant off-site toxicity. Studies also demonstrate that its stable isotopologue, I-127-PARPi, has minimal off-site toxicity when administered systemically.
MOLECULAR PHARMACEUTICS
(2021)
Review
Biochemistry & Molecular Biology
Harry J. Gould, Dennis Paul
Summary: Conventional cancer treatment often leads to resistance and severe adverse effects. However, targeted therapies have emerged as a more effective and selective approach for treating cancer by delivering lethal treatment to specific cancer cells while limiting adverse effects.
Review
Oncology
Cedric Leroux, Georgia Konstantinidou
Summary: The lack of early diagnosis, absence of suitable biomarkers, and resistance to available therapeutic options make pancreatic cancer one of the deadliest cancer types, necessitating the development of new therapeutic approaches. By considering the genetic and molecular profile of pancreatic tumors, potent and specific antitumor compounds can be developed to change this recalcitrant cancer type into a manageable one.
Article
Biochemistry & Molecular Biology
Botle Precious Setlai, Rodney Hull, Meshack Bida, Chrisna Durandt, Thanyani Victor Mulaudzi, Aristotelis Chatziioannou, Zodwa Dlamini
Summary: Immune response is crucial for patient prognosis and response to cancer treatment. Tumors evade immune surveillance by altering antigen processing pathways and the tumor microenvironment. This review highlights the molecular signaling pathways involved in immune suppression and how cancer cells manipulate antigen processing to escape immune surveillance. Additionally, the review explores the potential use of these pathways in precision medicine and understanding drug resistance.
Review
Biochemistry & Molecular Biology
Yinxing Zhu, Xuedan Zhu, Xiaowei Wei, Cuiju Tang, Wenwen Zhang
Summary: Molecular targeted therapy focusing on the HER-2 signaling pathway in gastric cancer has gained attention, with trastuzumab being the only approved drug for HER-2 positive advanced gastric cancer. Ongoing research is developing novel HER2-targeted drugs, and clinical trials are exploring various approaches to overcome resistance and improve treatment outcomes for HER2-positive gastric cancer patients.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2021)
Article
Multidisciplinary Sciences
Kazuhito Sakamoto, Patrick D. Radler, Barbara L. Wehde, Aleata A. Triplett, Hridaya Shrestha, Rosa-Maria Ferraiuolo, Foued Amari, Vincenzo Coppola, Apostolos Klinakis, Argiris Efstratiadis, Kay-Uwe Wagner
SCIENTIFIC REPORTS
(2020)
Review
Oncology
Rosa-Maria Ferraiuolo, Karoline C. Manthey, Marissa J. Stanton, Aleata A. Triplett, Kay-Uwe Wagner
Article
Audiology & Speech-Language Pathology
Shikha Tarang, Umesh Pyakurel, Michael D. Weston, Sarath Vijayakumar, Timothy Jones, Kay-Uwe Wagner, Sonia M. Rocha-Sanchez
Article
Multidisciplinary Sciences
Svenja Mertelmeyer, Matthias Weider, Tina Baroti, Simone Reiprich, Franziska Frob, C. Claus Stolt, Kay-Uwe Wagner, Michael Wegner
SCIENTIFIC REPORTS
(2020)
Review
Oncology
Rayane Dennaoui, Hridaya Shrestha, Kay-Uwe Wagner
Summary: Pancreatic cancer research has made significant progress in understanding the molecular and developmental processes involved in the genesis of this highly malignant tumor type. Various models, including chemical carcingen-induced and genetically engineered animal models, are being developed and analyzed to study the biological significance of new molecular targets and mechanisms contributing to pancreatic cancer onset and progression.
CANCER AND METASTASIS REVIEWS
(2021)
Article
Oncology
Gabriel B. Mpilla, Md Hafiz Uddin, Mohammed N. Al-Hallak, Amro Aboukameel, Yiwei Li, Steve H. Kim, Rafic Beydoun, Gregory Dyson, Erkan Baloglu, William T. Senapedis, Yosef Landesman, Kay-Uwe Wagner, Nerissa T. Viola, Bassel F. El-Rayes, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi
Summary: The study highlights the need for more effective targeted approaches to sensitize PNETs to everolimus for better treatment outcomes. The dual inhibitor KPT-9274 targeting PAK4-NAMPT, when combined with everolimus, showed promising results in inhibiting PNET growth and formation.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Endocrinology & Metabolism
Hyunji Byun, Sojung Kwon, Kay-Uwe Wagner, Hyejin Shin, Hyunjung Jade Lim
Summary: Deficiency of Tsg101 in uterine epithelium causes implantation failure and may be due to epithelial defects. The study found that UECs harbor a necroptotic machinery that responds to death-inducing signals.
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY
(2021)
Article
Multidisciplinary Sciences
Patrick D. Radler, Barbara L. Wehde, Aleata A. Triplett, Hridaya Shrestha, Jonathan H. Shepherd, Adam D. Pfefferle, Hallgeir Rui, Robert D. Cardiff, Charles M. Perou, Kay-Uwe Wagner
Summary: Claudin-low breast cancer is an aggressive subtype mainly composed of triple-negative mammary tumor cells with stem cell-like and mesenchymal features. The consistent activation of oncogenic RAS signaling and regulators of EMT play crucial roles in maintaining the cellular plasticity and characteristics of claudin-low mammary cancer cells.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Yunguang Sun, Ning Yang, Fransiscus E. Utama, Sameer S. Udhane, Junling Zhang, Amy R. Peck, Alicia Yanac, Katherine Duffey, John F. Langenheim, Vindhya Udhane, Guanjun Xia, Jess F. Peterson, Julie M. Jorns, Marja T. Nevalainen, Romain Rouet, Peter Schofield, Daniel Christ, Christopher J. Ormandy, Anne L. Rosenberg, Inna Chervoneva, Shirng-Wern Tsaih, Michael J. Flister, Serge Y. Fuchs, Kay-Uwe Wagner, Hallgeir Rui
Summary: A humanized prolactin mouse model was developed to establish therapy-naive ER+ breast cancer tumors and study treatment resistance mechanisms, revealing new insights into precision medicine approaches for this type of cancer.
Review
Oncology
Md. Hafiz Uddin, Mohammed Najeeb Al-Hallak, Philip A. Philip, Ramzi M. Mohammad, Nerissa Viola, Kay-Uwe Wagner, Asfar S. Azmi
Summary: Pancreatic cancer is the fourth leading cause of cancer death in the United States, with PDAC accounting for over 90% of cases and a low survival rate. MiRNAs have been identified as sensitive biomarkers in pancreatic cancer and are found in stable forms within exosomes. Further research on exosomal miRNAs is necessary for improved diagnostic, prognostic, and therapeutic strategies.
Article
Medicine, Research & Experimental
Cancan Lyu, Yuanchao Ye, Maddison M. Lensing, Kay-Uwe Wagner, Ronald J. Weigel, Songhai Chen
Summary: In HER2(+) breast cancer, overactivation of HER2 leads to aberrant G(i/o)-GPCR signaling, promoting cancer progression and resistance to HER2-targeted therapy. Pharmacologically deactivating GPCR signaling can block tumor growth and enhance therapeutic efficacy.
Article
Multidisciplinary Sciences
Patrick D. Radler, Kerry Vistisen, Aleata A. Triplett, Rayane Dennaoui, Yong Li, Hridaya Shrestha, Rosa-Maria Ferraiuolo, Amalraj Thangasamy, Dieter Saur, Kay-Uwe Wagner
Summary: The researchers developed a transgenic mouse line expressing an optimized Flp recombinase, demonstrating the versatile applicability of the new MMTV-Flp strain in manipulating genes in mammary gland cells. By combining two recombinases, genes can be deleted or activated in established tumors, showing the feasibility of gene manipulation in neoplastic mammary epithelial cells.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Madison N. Wicker, Kay-Uwe Wagner
Summary: Cellular plasticity, the ability of cells to change their identity, plays a crucial role in mammary gland development and breast cancer progression. This review provides a comprehensive overview of the factors and mechanisms that promote cellular plasticity in the mammary gland. It discusses changes in cell identity during normal development, the role of the gestation cycle, and highlights the importance of the microenvironment and extracellular matrix. The review also explores cellular reprogramming during mammary tumorigenesis, focusing on the origin of basal-like breast cancers and the role of oncogenic signaling networks. Additionally, recent advances in genetically engineered models to study cellular plasticity in vivo are discussed.
Article
Biochemistry & Molecular Biology
Dai Le, Soyeon Lim, Kwang Wook Min, Joon Woo Park, Youjoung Kim, Taejeong Ha, Kyeong Hwan Moon, Kay-Uwe Wagner, Jin Woo Kim
Summary: The distribution of membrane proteins in RPE varies during different developmental stages, indicating developmental regulation of protein trafficking. Deletion of Tsg101 disrupts RPE polarity, leading to irregular aggregates and non-polarized distribution of cell adhesion proteins and activation of epidermal growth factor receptor signaling, highlighting the importance of ESCRT-mediated protein trafficking for RPE cell polarity development and maintenance.
MOLECULES AND CELLS
(2021)
Article
Oncology
Hassan Mohammed Khair Ibrahim Higazi, Long He, Jing Fang, Fei Sun, Qing Zhou, Teng Huang, Xiaoyu He, Yi Wang, Fei Xiong, Ping Yang, Qilin Yu, Jinxiu Li, Kay-Uwe Wagner, Bao-Ling Adam, Shu Zhang, Cong-Yi Wang
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2019)